Myriad Begin Period Cash Flow vs Depreciation Analysis

MYGN Stock

USD 12.96 0.20 1.57%

Myriad Genetics financial indicator trend analysis is infinitely more than just investigating Myriad Genetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Myriad Genetics is a good investment. Please check the relationship between Myriad Genetics Begin Period Cash Flow and its Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Myriad Genetics Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have weak relationship.

The correlation between Myriad Genetics' Begin Period Cash Flow and Depreciation is 0.35. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Myriad Genetics, assuming nothing else is changed. The correlation between historical values of Myriad Genetics' Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Myriad Genetics are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Myriad Genetics' Begin Period Cash Flow and Depreciation go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Myriad Genetics value has been used up. For tax purposes Myriad Genetics can deduct the cost of the tangible assets it purchases as business expenses. However, Myriad Genetics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Myriad Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Myriad Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.At this time, Myriad Genetics' Tax Provision is very stable compared to the past year. As of the 24th of January 2025, Issuance Of Capital Stock is likely to grow to about 142 M, while Selling General Administrative is likely to drop about 468.6 M.

	2022	2023	2024	2025 (projected)
Total Revenue	678.4M	753.2M	866.2M	909.5M
Depreciation And Amortization	55.9M	61.9M	71.2M	74.7M

Total Revenue Depreciation And Amortization

Myriad Genetics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Common Stock	Current Deferred Revenue	Inventory	Good Will
Total Assets		0.68	0.57	0.69	0.94	0.39	0.18	-0.25	0.89	0.61	0.83	-0.55	-0.11	0.47	0.75	-0.17	0.62	0.78	0.23	0.31	0.72	-0.32	0.61	-0.55	0.66	0.86
Short Long Term Debt Total	0.68		0.57	0.4	0.57	0.41	0.4	-0.37	0.53	0.23	0.6	-0.23	-0.08	0.49	0.68	0.1	0.54	0.68	0.22	0.24	0.56	-0.18	0.55	-0.51	0.48	0.57
Other Current Liab	0.57	0.57		0.91	0.39	0.71	0.21	-0.69	0.51	0.62	0.71	-0.08	-0.13	0.29	0.76	-0.16	0.78	0.84	0.06	-0.08	0.67	-0.5	0.41	-0.36	0.41	0.6
Total Current Liabilities	0.69	0.4	0.91		0.54	0.7	0.17	-0.63	0.64	0.68	0.82	-0.26	-0.18	0.28	0.78	-0.21	0.8	0.87	0.02	-0.08	0.71	-0.53	0.42	-0.39	0.48	0.73
Total Stockholder Equity	0.94	0.57	0.39	0.54		0.28	0.07	-0.12	0.91	0.6	0.71	-0.47	0.09	0.6	0.57	-0.17	0.56	0.59	0.4	0.39	0.73	-0.1	0.69	-0.67	0.78	0.73
Property Plant And Equipment Net	0.39	0.41	0.71	0.7	0.28		0.38	-0.95	0.48	0.4	0.65	0.27	-0.28	0.34	0.62	-0.15	0.92	0.65	-0.15	-0.42	0.59	-0.55	0.41	-0.37	0.3	0.52
Net Debt	0.18	0.4	0.21	0.17	0.07	0.38		-0.31	0.27	-0.34	0.42	-0.1	-0.51	-0.02	0.59	-0.06	0.31	0.36	-0.45	-0.17	0.37	-0.41	-0.06	-0.07	-0.04	0.44
Retained Earnings	-0.25	-0.37	-0.69	-0.63	-0.12	-0.95	-0.31		-0.31	-0.37	-0.49	-0.37	0.27	-0.3	-0.52	0.06	-0.83	-0.56	0.17	0.53	-0.44	0.52	-0.39	0.28	-0.18	-0.38
Accounts Payable	0.89	0.53	0.51	0.64	0.91	0.48	0.27	-0.31		0.56	0.79	-0.3	-0.15	0.46	0.66	-0.3	0.67	0.63	0.13	0.18	0.8	-0.37	0.57	-0.57	0.65	0.81
Cash	0.61	0.23	0.62	0.68	0.6	0.4	-0.34	-0.37	0.56		0.46	-0.07	0.27	0.38	0.39	-0.17	0.56	0.51	0.42	-0.09	0.42	-0.15	0.5	-0.25	0.41	0.39
Non Current Assets Total	0.83	0.6	0.71	0.82	0.71	0.65	0.42	-0.49	0.79	0.46		-0.49	-0.44	0.21	0.93	-0.24	0.79	0.93	-0.16	0.16	0.8	-0.68	0.33	-0.42	0.5	0.97
Non Currrent Assets Other	-0.55	-0.23	-0.08	-0.26	-0.47	0.27	-0.1	-0.37	-0.3	-0.07	-0.49		0.21	0.12	-0.48	0.06	0.02	-0.48	0.02	-0.6	-0.28	0.19	0.03	0.08	-0.22	-0.59
Cash And Short Term Investments	-0.11	-0.08	-0.13	-0.18	0.09	-0.28	-0.51	0.27	-0.15	0.27	-0.44	0.21		0.53	-0.42	0.16	-0.12	-0.36	0.93	0.17	-0.03	0.85	0.42	-0.32	0.33	-0.53
Common Stock Shares Outstanding	0.47	0.49	0.29	0.28	0.6	0.34	-0.02	-0.3	0.46	0.38	0.21	0.12	0.53		0.17	0.26	0.53	0.19	0.72	0.1	0.54	0.42	0.97	-0.88	0.83	0.15
Non Current Liabilities Total	0.75	0.68	0.76	0.78	0.57	0.62	0.59	-0.52	0.66	0.39	0.93	-0.48	-0.42	0.17		-0.15	0.75	0.95	-0.16	0.07	0.74	-0.64	0.27	-0.31	0.35	0.9
Other Current Assets	-0.17	0.1	-0.16	-0.21	-0.17	-0.15	-0.06	0.06	-0.3	-0.17	-0.24	0.06	0.16	0.26	-0.15		-0.14	-0.14	0.19	-0.31	-0.31	0.43	0.17	-0.08	0.01	-0.26
Other Stockholder Equity	0.62	0.54	0.78	0.8	0.56	0.92	0.31	-0.83	0.67	0.56	0.79	0.02	-0.12	0.53	0.75	-0.14		0.77	0.09	-0.14	0.82	-0.46	0.6	-0.6	0.58	0.67
Total Liab	0.78	0.68	0.84	0.87	0.59	0.65	0.36	-0.56	0.63	0.51	0.93	-0.48	-0.36	0.19	0.95	-0.14	0.77		-0.08	0.09	0.7	-0.63	0.33	-0.34	0.41	0.88
Total Current Assets	0.23	0.22	0.06	0.02	0.4	-0.15	-0.45	0.17	0.13	0.42	-0.16	0.02	0.93	0.72	-0.16	0.19	0.09	-0.08		0.3	0.21	0.75	0.67	-0.55	0.58	-0.23
Short Term Debt	0.31	0.24	-0.08	-0.08	0.39	-0.42	-0.17	0.53	0.18	-0.09	0.16	-0.6	0.17	0.1	0.07	-0.31	-0.14	0.09	0.3		0.32	0.15	0.11	-0.37	0.45	0.21
Net Receivables	0.72	0.56	0.67	0.71	0.73	0.59	0.37	-0.44	0.8	0.42	0.8	-0.28	-0.03	0.54	0.74	-0.31	0.82	0.7	0.21	0.32		-0.33	0.59	-0.74	0.76	0.74
Short Term Investments	-0.32	-0.18	-0.5	-0.53	-0.1	-0.55	-0.41	0.52	-0.37	-0.15	-0.68	0.19	0.85	0.42	-0.64	0.43	-0.46	-0.63	0.75	0.15	-0.33		0.27	-0.21	0.17	-0.7
Common Stock	0.61	0.55	0.41	0.42	0.69	0.41	-0.06	-0.39	0.57	0.5	0.33	0.03	0.42	0.97	0.27	0.17	0.6	0.33	0.67	0.11	0.59	0.27		-0.87	0.84	0.29
Current Deferred Revenue	-0.55	-0.51	-0.36	-0.39	-0.67	-0.37	-0.07	0.28	-0.57	-0.25	-0.42	0.08	-0.32	-0.88	-0.31	-0.08	-0.6	-0.34	-0.55	-0.37	-0.74	-0.21	-0.87		-0.96	-0.36
Inventory	0.66	0.48	0.41	0.48	0.78	0.3	-0.04	-0.18	0.65	0.41	0.5	-0.22	0.33	0.83	0.35	0.01	0.58	0.41	0.58	0.45	0.76	0.17	0.84	-0.96		0.44
Good Will	0.86	0.57	0.6	0.73	0.73	0.52	0.44	-0.38	0.81	0.39	0.97	-0.59	-0.53	0.15	0.9	-0.26	0.67	0.88	-0.23	0.21	0.74	-0.7	0.29	-0.36	0.44

Click cells to compare fundamentals

Myriad Genetics Account Relationship Matchups

Myriad Genetics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.4B	1.3B	1.2B	1.1B	1.3B	670.7M
Other Current Liab	104.9M	122.9M	60.1M	109.3M	125.7M	132.0M
Total Current Liabilities	145.9M	204.3M	137.2M	155.9M	179.3M	188.2M
Total Stockholder Equity	881M	967.8M	885.8M	783.2M	900.7M	529.5M
Property Plant And Equipment Net	100.4M	125.3M	187.3M	180.6M	207.7M	218.1M
Net Debt	(117M)	(166.1M)	88.1M	20M	23M	24.2M
Retained Earnings	(227M)	(254.2M)	(366.2M)	(629.5M)	(566.6M)	(538.2M)
Accounts Payable	20.5M	29.6M	28.8M	25.8M	29.7M	17.0M
Cash	117M	258.4M	56.9M	132.1M	151.9M	92.1M
Non Current Assets Total	1.0B	835.9M	924.1M	832.9M	957.8M	1.0B
Non Currrent Assets Other	(1.0B)	8.3M	15.5M	15.4M	13.9M	14.6M
Common Stock Shares Outstanding	74.8M	78M	80.6M	82.8M	95.2M	75.0M
Non Current Liabilities Total	224.8M	148.6M	175.7M	207.4M	238.5M	250.4M
Other Current Assets	122.1M	38.4M	20.4M	36.4M	41.9M	55.5M
Other Stockholder Equity	1.1B	1.2B	1.3B	1.4B	1.6B	1.7B
Total Liab	537.8M	352.9M	312.9M	363.3M	417.8M	438.7M
Total Current Assets	389.4M	484.8M	274.6M	313.6M	360.6M	306.6M
Net Receivables	89.5M	91.3M	101.6M	114.3M	131.4M	138.0M
Short Term Investments	33.7M	81.4M	58M	8.8M	10.1M	9.6M
Inventory	27.1M	15.3M	20.1M	22M	25.3M	26.6M
Good Will	329.2M	239.2M	286.8M	287.4M	330.5M	245.9M
Intangible Assets	578.8M	404.1M	379.7M	349.5M	401.9M	339.7M

Pair Trading with Myriad Genetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Myriad Stock

0.91	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.88	LLY	Eli Lilly	Pair Corr
0.78	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Myriad Stock

0.71	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.7	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.64	GILD	Gilead Sciences Sell-off Trend	Pair Corr
0.34	MLAB	Mesa Laboratories	Pair Corr

The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.

The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:

How To Invest In Myriad

Details

Is Myriad Stock a good investment?

Details

What is Myriad Genetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.28)

Revenue Per Share

9.205

Quarterly Revenue Growth

0.112

Return On Assets

(0.05)

Return On Equity

(0.16)

The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Myriad Begin Period Cash Flow vs Depreciation Analysis

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Depreciation

Myriad Genetics fundamental ratios Correlations

Myriad Genetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Myriad Genetics fundamental ratios Accounts

Pair Trading with Myriad Genetics

Moving together with Myriad Stock

Moving against Myriad Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 0.97	Non Current Assets Total
Common Stock	+ 0.97	Common Stock Shares Outstanding
Total Liab	+ 0.95	Non Current Liabilities Total
Total Stockholder Equity	+ 0.94	Total Assets
Non Current Liabilities Total	+ 0.93	Non Current Assets Total
Total Liab	+ 0.93	Non Current Assets Total

Inventory	- 0.96	Current Deferred Revenue
Retained Earnings	- 0.95	Property Plant And Equipment Net
Current Deferred Revenue	- 0.88	Common Stock Shares Outstanding
Current Deferred Revenue	- 0.87	Common Stock
Other Stockholder Equity	- 0.83	Retained Earnings
Current Deferred Revenue	- 0.74	Net Receivables